Abstract
The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Current Pharmaceutical Biotechnology
Title: Rodent Models of Persistent Pain in Drug Discovery and Development
Volume: 12 Issue: 10
Author(s): William A. Eckert
Affiliation:
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Abstract: The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Export Options
About this article
Cite this article as:
A. Eckert William, Rodent Models of Persistent Pain in Drug Discovery and Development, Current Pharmaceutical Biotechnology 2011; 12 (10) . https://dx.doi.org/10.2174/138920111798357456
DOI https://dx.doi.org/10.2174/138920111798357456 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Signaling Pathways Involved in Physiopathology of Pancreatic β -Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry Towards Understanding the Roles of Prohibitins, Multi-Functional Regulator Proteins
Current Chemical Biology Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Approaches for the Cure of Type 1 Diabetes by Cellular and Gene Therapy
Current Gene Therapy Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Dipeptidyl Peptidase IV Inhibitors: The Next Generation of New Promising Therapies for the Management of Type 2 Diabetes
Current Topics in Medicinal Chemistry Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Pain - Unmet Need and Emerging Targets & Therapies (Guest Editor: Sivaram Pillarisetti)]
CNS & Neurological Disorders - Drug Targets Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy